New experimental evidence supports the idea that future therapeutic strategies for treating cardiovascular disease could target sites within the brain. Our recent study demonstrates the existence of ...

Beta-blocker use is associated with a 34% reduction of onset in premanifest Huntington disease (preHD) and slower progression in early motor-manifest Huntington disease (mmHD), new research shows. In ...

The evidence supporting beta-blocker therapy after myocardial infarction was established before the introduction of modern coronary reperfusion therapy and secondary prevention strategies. In an ...

The appropriate duration of beta-blocker treatment after a heart attack (a myocardial infarction [MI]) is unknown in patients who do not need to take beta-blockers for another reason. In the ABYSS ...

Madrid, Spain – 30 August 2025: Beta-blocker therapy significantly reduced a composite endpoint of all-cause mortality and major adverse cardiovascular events compared with no beta-blocker therapy in ...

A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa Health Care researchers. Using clinical information from a large, ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...